V900339

应用筛选条件

关键词:'V900339'

显示 1-30 共 139 条结果关于 "V900339" 范围论文

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.

Elias Jabbour et al.

American journal of hematology, 89(4), 395-398 (2014-01-01)

Outcomes of patients with acute myeloid leukemia (AML) who are refractory to high-dose Cytarabine (HiDAC)-based induction are dismal. Allogeneic hematopoietic stem cell transplantation (AHSCT) as initial salvage may be effective and potentially superior to conventional salvage chemotherapy. Eighteen percent (285

Multiple myeloma: a descriptive study of 217 Egyptian patients.

Noha M El Husseiny et al.

Annals of hematology, 93(1), 141-145 (2013-07-31)

Multiple myeloma is a neoplasm of plasma cells that results in the overproduction of light and heavy chain monoclonal immunoglobulins. The incidence rate increases with age, particularly after 40 years, and is higher in men. To determine the clinical and

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Aziz Nazha et al.

American journal of hematology, 88(11), 961-966 (2013-07-24)

Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin, and cytarabine (CIA) in relapsed and refractory AML had shown an overall response rate (ORR) of 48%.

Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.

Sachit A Patel et al.

Journal of pediatric hematology/oncology, 36(6), 491-494 (2013-12-11)

Hematopoietic stem cell transplantation (HSCT) remains the only curative option for most patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and relapse rates after transplant range from 26% to 58%. We report the successful use of second HSCT after

Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.

Sarah A Buckley et al.

American journal of hematology, 89(4), 423-428 (2014-01-03)

Intensive chemotherapy for newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) is associated with significant treatment-related morbidity and mortality. Herein, we investigate how pretreatment characteristics relate to early adverse outcomes in such patients, studying 205 consecutive individuals receiving

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Arne Kolstad et al.

Blood, 123(19), 2953-2959 (2014-03-22)

The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years

Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.

Melanie Kripp et al.

International journal of nanomedicine, 3(4), 397-401 (2008-01-01)

Liposomal encapsulated cytarabine (DepoCyte, Mundipharma GmbH, Limburg/Lahn, Germany) is a slow-release formulation of conventional cytarabine. It is licensed for intrathecal use in patients with lymphomatous and leukemic meningitis. DepoCyte obtained superior response rates, improved patient quality of life and improved

Is cytarabine required in the treatment of acute promyelocytic leukemia?

Lionel Adès et al.

Current hematologic malignancy reports, 1(2), 122-125 (2006-06-01)

Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia. Many studies have shown that treatment with all-trans retinoic acid (ATRA), followed

Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.

Skjalg Bruheim et al.

Anticancer research, 33(9), 3615-3621 (2013-09-12)

The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5'-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.

Bob Löwenberg

Blood, 121(1), 26-28 (2013-01-05)

High-dose cytarabine applied during remission induction or as consolidation after attainment of a complete remission has become an established element in the treatment of adults with acute myeloid leukemia. Recent evidence has challenged the need for these exceptionally high-dose levels

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.

Hagop M Kantarjian et al.

Cancer, 119(14), 2611-2619 (2013-04-23)

In this phase 2 study, the authors evaluated the efficacy, safety, and tolerability of the Aurora B kinase inhibitor barasertib compared with low-dose cytosine arabinoside (LDAC) in patients aged ≥ 60 years with acute myeloid leukemia (AML). Patients were randomized

Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case.

Man Fai Law et al.

Annals of hematology, 93(12), 2083-2085 (2014-05-02)

GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis.

Qiang Xiao et al.

Annals of hematology, 93(8), 1381-1390 (2014-07-06)

Glutathione S-transferases (GSTs) contribute to the metabolism of different xenobiotics and anticancer drugs and confer protection against oxidative stress thus may influence the treatment outcome of acute myeloid leukemia (AML). Studies regarding the association between GSTT1 and GSTM1 polymorphisms and

Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.

Shelby D Reed et al.

PharmacoEconomics, 26(5), 435-446 (2008-04-24)

For trials in which participants are followed beyond the main study period to assess long-term outcomes, economic evaluations conducted using short-term data should be systematically updated to reflect new information. We used 60-month survival data from the IRIS (International Randomized

Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.

Koji Kato et al.

Pediatric blood & cancer, 61(4), 712-716 (2014-01-01)

The conventional conditioning regimen for patients with leukemia prior to allogeneic stem cell transplantation is myeloablation to eradicate residual leukemic cells and host immunocompetent cells. This helps prevent leukemic relapse as well as rejection after transplantation. A myeloablative conditioning regimen

Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.

Noriyoshi Iriyama et al.

Annals of hematology, 93(6), 957-963 (2014-01-21)

Recently, the presence of CEBPA mutation was identified as an important prognostic factor for normal karyotype (NK) acute myeloid leukemia (AML). Because AML with CEBPA mutation is closely associated with CD7, CD15, CD34, and HLA-DR expression, we investigated the prognostic

Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.

Celalettin Eroglu et al.

American journal of clinical oncology, 38(1), 68-73 (2013-04-09)

To assess the outcomes of overall survival and posttransplantation survival in patients with Hodgkin lymphoma (HL) undergoing autologous stem cell transplantation (ASCT) because of the development of relapse or resistance after chemotherapy (CT) or CT plus radiotherapy (combined modality treatment

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Eric R Gamazon et al.

Blood, 121(21), 4366-4376 (2013-03-30)

A whole-genome approach was used to investigate the genetic determinants of cytarabine-induced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the

Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.

Yuki Kojima et al.

Japanese journal of clinical oncology, 44(4), 318-323 (2014-02-22)

Acquired immunodeficiency syndrome-related non-Hodgkin lymphoma is treated similarly to non-acquired immunodeficiency syndrome lymphoma, but it is not clear whether highly intensive regimens are beneficial for acquired immunodeficiency syndrome-related Burkitt lymphoma. We conducted a multicenter retrospective survey to clarify the clinical

A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.

Elizabeth Anderson et al.

Leukemia research, 37(6), 690-696 (2013-03-12)

This study evaluates an in vitro biosensor assay capable of detecting the intracellular levels of the tri-phosphorylated form of cytarabine (Ara-CTP) within one working day. The biosensor predicted the response of seven leukaemic cell lines with varying known sensitivities to

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

Patrick G Morris et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(31), 3971-3979 (2013-10-09)

A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphoma. Patients received induction chemotherapy with R-MPV (five to seven

When the eye gives it all: diagnosis of relapsing acute myeloblastic leukemia with anterior chamber tap of a chronic hypopyon.

Valerie Touitou et al.

American journal of hematology, 89(8), 858-859 (2014-08-29)

[Kaposiform haemangioendothelioma associated with B-cell acute lymphoblastic leukemia].

F Fichel et al.

Annales de dermatologie et de venereologie, 140(3), 209-214 (2013-03-08)

Herein, we report the first case of kaposiform haemangioendothelioma (KHE) associated with acute B-lymphoblastic leukemia (B-ALL). A five-month-old infant presented a plaque of angiomatous appearance on the forearm that had increased in volume since birth, as well as pallor and

A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.

Kenneth F Bradstock et al.

British journal of haematology, 167(5), 618-625 (2014-08-22)

Gastrointestinal toxicity, including oral mucositis, is a frequent complication of intensive combination chemotherapy for acute myeloid leukaemia (AML) and contributes substantially to treatment-related mortality. We conducted a placebo-controlled randomized trial to evaluate the efficacy of palifermin (keratinocyte growth factor), given

Enlargement and multinucleation of u937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents.

Matthew Trendowski et al.

Anticancer research, 35(1), 65-76 (2015-01-01)

Cytochalasin B is a mycogenic toxin that preferentially damages malignant cells through multiple mechanisms. The microfilament-disrupting agent inhibits cytokinesis, producing enlarged and multinucleated neoplastic cells without enlarging or producing multinucleated normal cells. In addition, cytochalasin B has been shown to

Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.

Daniel Nowak et al.

Experimental hematology, 43(1), 32-43 (2014-12-03)

The use of genome-wide copy-number analysis and massive parallel sequencing has revolutionized the understanding of the clonal architecture of pediatric acute lymphoblastic leukemia (ALL) by demonstrating that this disease is composed of highly variable clonal ancestries following the rules of

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Hiba Ahmad Zahreddine et al.

Nature, 511(7507), 90-93 (2014-05-30)

Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Terzah M Horton et al.

Pediatric blood & cancer, 61(10), 1754-1760 (2014-07-01)

This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiating cells (AML-LIC) before and after treatment.

Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.

Michaela Liedtke et al.

Leukemia research, 38(12), 1441-1445 (2014-12-03)

The survival of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor. We performed a retrospective analysis of 40 patients treated with five days of mitoxantrone 8mg/m(2)/day, etoposide 100mg/m(2)/day, and cytarabine 1000mg/m(2)/day (MEC). The complete remission rate was

Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.

Cheng-Han Wu et al.

Annals of hematology, 93(6), 1079-1081 (2013-10-31)

1/5